Core 2 - Clinical and Tissue Core

核心 2 - 临床和组织核心

• 批准号: 10555736
• 负责人: herve Avet loiseau
• 金额: $ 22.92万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555736
• 关键词: Acceleration; Age; Architecture; Biological; Biological Specimen Banks; Biomedical Research; Blood specimen; Bortezomib; Cells; Clinical; Clinical Data; Clinical Protocols; Clinical Research; Clinical Trials; Clinical Trials Database; Collection; Complex; Computerized Medical Record; Confidential Information; DNA; DNA sequencing; Dana-Farber Cancer Institute; Data; Data Analyses; Data Sources; Databases; Dexamethasone; Dose; Epidemiology; Floods; Funding; Future; Genetic; Genomics; Goals; Health; Human Characteristics; Institution; Intuition; Link; Modernization; Molecular Genetics; Monoclonal gammopathy of uncertain significance; Multiple Myeloma; Online Systems; Patients; Plasma; Procedures; Process; Public Domains; Publications; Quality Control; RNA; Research; Research Personnel; Research Support; Resources; Sampling; Secure; Serum; Site; Source; Standardization; Structure; System; Technology; Thalidomide; Tissue Banks; Tissue Sample; Tissues; Training; Transplantation; Treatment Protocols; Work; cancer genomics; central database; clinical database; clinical practice; clinically relevant; comparative effectiveness; complex data; data integration; data modeling; data repository; genomic data; graphical user interface; human disease; lenalidomide; next generation; preservation; programs; response; transcriptome sequencing; tumor; web portal

Project Summary – Core 2 – Clinical and Tissue Core CHU-Toulouse / DFCI Modern biomedical research is being transformed by what is increasingly becoming a flood of information. Electronic medical records have opened unprecedented opportunities for studies investigating a wide range of problems ranging from epidemiological aspects of human disease to the comparative effectiveness of various treatment protocols. Similarly, genomic technologies such as next-generation DNA and RNA sequencing from bulk and single cell have opened a floodgate of data and information that promises to shed light on the complex nature of human disease. In this information-rich age, one of the greatest challenges is therefore no longer generating data, but effectively integrating it so that it can be used to our advantage. Because clinical practice has long been separate from the research enterprise at most academic health centers, a situation has evolved in which clinical and research data exist in separate, often incompatible domains with a variety of technical, institutional, and organizational barriers between them. Further limiting our ability to extract the maximal value of the data we have available is the fact that data within institutions is rarely integrated with the vast body of data available in the public domain. Similarly, another need is to aid Investigators better characterize and identify tumor biologic and molecular genetic correlates for response, progression, and survival by collecting, preserving and distributing tissue derived from patients on clinical protocol. A large sources of clinical data will be used in this program project. The data for this large IFM/DFCI collaborative clinical trials are collected in an established clinical trials database at the IFM and DFCI. In the previous funding period this core has supported number of clinical publications by providing database support and help projects generate large volume of genomics data by providing quality-controlled tissue sample. This Core will continue to have as its main goals to create, maintain, and quality control the clinical database (Specific Aim 1); and to collect, transport, process and store tissue samples from all sites utilizing standardized procedures in centralized tissue banks (Specific Aim 2); and to develop an integrated database to incorporate the sample tracking and oncogenomic information with the relevant clinical data from the clinical trials database with web based query capabilities (Specific Aim 3).

项目总结-核心2 -临床和组织核心CHU-Toulouse / DFCI 现代生物医学研究正在被日益成为信息洪流的东西所改变。 电子医疗记录为研究广泛的疾病提供了前所未有的机会。 从人类疾病的流行病学方面到各种疾病的比较有效性， 治疗方案。同样，基因组技术，如下一代DNA和RNA测序， 大块和单细胞已经打开了一个数据和信息的闸门，有望揭示复杂的 人类疾病的本质因此，在这个信息丰富的时代，最大的挑战之一不再是 产生数据，但有效地整合它，以便它可以用于我们的优势。因为临床实践 长期以来，在大多数学术健康中心， 其中临床和研究数据存在于分离、常常不兼容的领域中， 他们之间的制度和组织障碍。进一步限制了我们提取最大值的能力 我们现有的数据中，有一个事实是，机构内部的数据很少与大量数据相结合， 在公共领域可用。同样，另一个需要是帮助调查人员更好地描述和识别 肿瘤生物学和分子遗传学与缓解、进展和生存相关， 以及根据临床协议分发来自患者的组织。将使用大量临床数据来源， 这个节目项目。这个大型IFM/DFCI合作临床试验的数据收集在一个既定的 IFM和DFCI的临床试验数据库。在上一个供资期间，该核心基金支助了若干 通过提供数据库支持和帮助项目生成大量基因组学数据， 通过提供质量受控的组织样本这个核心将继续以创造为主要目标， 维护和质量控制临床数据库（具体目标1）;以及收集、运输、处理和储存 使用集中组织库中的标准化程序从所有研究中心采集的组织样本（具体目标2）;以及 开发一个综合数据库，将样本跟踪和癌基因组信息与 临床试验数据库中的相关临床数据，具有基于网络的查询功能（具体目标3）。